Prijeđi na sadržaj

Doksantrin

Izvor: Wikipedija
Doksantrin
(IUPAC) ime
(6aS,12bR)-6a,7,8,12b-tetrahidro-6H-hromeno[3,4-c]izohinolin-2,3-diol
Klinički podaci
Identifikatori
ATC kod nije dodeljen
PubChem[1][2] 15981509
Hemijski podaci
Formula C16H15NO3 
Mol. masa 269,295 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Doksantrin je sintetičko jedinjenje koje je potentan i selektivan pun agonist dopaminskog D1 receptora.[3][4]

Reference

[uredi | uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). „trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist”. Journal of Medicinal Chemistry 49 (23): 6848–57. DOI:10.1021/jm0604979. PMID 17154515. 
  4. Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). „Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 19 (2): 138–46. DOI:10.1016/j.euroneuro.2008.10.002. PMC 2636714. PMID 19028082. 

Vanjske veze

[uredi | uredi kod]